Disclaimer
The stock market is subject to significant volatility and inherent risks. Investing in stocks involves potential losses and is not guaranteed to generate profits. Prices of stocks can fluctuate unpredictably, We do not give any buy/sell tips. This article is for Educational purposes only.
The Senores Pharmaceuticals IPO is a highly anticipated book-built issue worth ₹582.11 crores. It comprises a fresh issue of 1.28 crore shares, raising ₹500.00 crores, and an offer for sale (OFS) of 0.21 crore shares, aggregating ₹82.11 crores. This IPO opens for subscription on December 20, 2024, and closes on December 24, 2024. Investors keen on tracking the IPO subscription status can find updates on platforms like IPO Watch. The allotment for the issue is scheduled to be finalized on Thursday, December 26, 2024, with the listing date tentatively set for Monday, December 30, 2024, on the BSE and NSE.
The price band for the Senores Pharmaceuticals IPO is fixed at ₹372 to ₹391 per share, with a minimum lot size of 38 shares. Retail investors can participate with a minimum investment of ₹14,858, while sNII and bNII investors require ₹2,08,012 (14 lots) and ₹10,10,344 (68 lots), respectively. Monitoring the IPO GMP live offers insights into market expectations, while platforms providing IPO GMP updates can help assess potential listing gains.
The lead managers for this IPO are Equirus Capital Private Limited, Ambit Private Limited, and Nuvama Wealth Management Limited, with Link Intime India Private Ltd as the registrar. Investors can check the IPO allotment status via the registrar’s portal or the IPO allotment BSE platform. This IPO is an exciting opportunity for participants to engage in the growth journey of Senores Pharmaceuticals while staying informed through resources on IPO subscription status, IPO allotment, and live updates on IPO GMP.
| Details | Information |
|---|---|
| IPO Date | December 20, 2024 to December 24, 2024 |
| Listing Date | December 30, 2024 |
| Face Value | ₹10 per share |
| Price Band | ₹372 to ₹391 per share |
| Lot Size | 38 Shares |
| Total Issue Size | 1,48,87,723 shares (aggregating up to ₹582.11 Cr) |
| Fresh Issue | 1,27,87,723 shares (aggregating up to ₹500.00 Cr) |
| Offer for Sale | 21,00,000 shares of ₹10 (aggregating up to ₹82.11 Cr) |
| Issue Type | Book Built Issue IPO |
| Listing At | BSE, NSE |
| Share Holding Pre-Issue | 3,32,65,865 shares |
| Share Holding Post Issue | 4,60,53,588 shares |
| Event | Date |
|---|---|
| IPO Open Date | Friday, December 20, 2024 |
| IPO Close Date | Tuesday, December 24, 2024 |
| Basis of Allotment | Thursday, December 26, 2024 |
| Initiation of Refunds | Friday, December 27, 2024 |
| The credit of Shares to Demat | Friday, December 27, 2024 |
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 38 | ₹14,858 |
| Retail (Max) | 13 | 494 | ₹1,93,154 |
| S-HNI (Min) | 14 | 532 | ₹2,08,012 |
| S-HNI (Max) | 67 | 2,546 | ₹9,95,486 |
| B-HNI (Min) | 68 | 2,584 | ₹10,10,344 |
| Investor Category | Shares Offered |
|---|---|
| QIB Shares Offered | Not less than 75% of the Net Issue |
| Retail Shares Offered | Not more than 10% of the Net Issue |
| NII (HNI) Shares Offered | Not more than 15% of the Net Issue |
| Period Ended | 30 Sep 2024 | 31 Mar 2024 | 31 Mar 2023 | 31 Mar 2022 |
|---|---|---|---|---|
| Assets | 678.08 | 621.88 | 131.05 | 59.15 |
| Revenue | 183.35 | 217.34 | 39.02 | 14.63 |
| Profit After Tax | 23.94 | 32.71 | 8.43 | 0.99 |
| Net Worth | 319.06 | 231.71 | 45.5 | 36.59 |
| Reserves and Surplus | 263.36 | 175.94 | 35.25 | 25.37 |
| Total Borrowing | 242.03 | 248.38 | 60.76 | 14.21 |
The Senores Pharmaceuticals IPO presents a significant investment opportunity with its robust pricing and market potential. Investors can monitor the IPO subscription status to stay updated on demand and check the IPO allotment status through the registrar or BSE IPO allotment portal once finalized. Tracking the IPO GMP live updates can provide insights into expected listing gains, making it a valuable tool for both retail and institutional investors. Platforms like IPO watch offer comprehensive details to help make informed decisions. With its strategic pricing band and strong financial backing, this IPO is poised to attract substantial interest from the market. Stay informed on all aspects, including IPO GMP, allotment updates, and subscription trends, to make the most of this opportunity.
